AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12751984 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 75
Study 12751984 — intervention group
Group type: COMPARATOR
Intervention: Non-Contingency Management (non-CM)
Number of subjects: 75
Study 12751984 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI)
Number of subjects: 75
Study 12751984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 12040471 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF starting on day +1
Number of subjects: 87
Study 12040471 — intervention group
Group type: COMPARATOR
Intervention: G-CSF starting on day +5
Number of subjects: 87
Study 9687125 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (TT)
Number of subjects: 99
Study 9687125 — intervention group
Group type: COMPARATOR
Intervention: Sham Therapeutic Touch (sham TT)
Number of subjects: 99
Study 9687125 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 99
Study 8077802 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (recombinant human erythropoietin)
Number of subjects: 40
Study 8077802 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 40
Study 8077802 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 40
Study 8077802 — intervention group
Group type: COMPARATOR
Intervention: Gallopamil
Number of subjects: 40
Study 8077802 — intervention group
Group type: COMPARATOR
Intervention: Ketanserine
Number of subjects: 40
Study 2521696 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF infusion
Number of subjects: 6
Study 2521696 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 6
Study 4615786 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus nandrolone phenylpropionate
Number of subjects: 2
Study 4615786 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide alone
Number of subjects: 2
Study 31856691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 1534
Study 31856691 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1534
Study 30994720 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Ventricular (LV) Pacing
Number of subjects: 91
Study 30994720 — intervention group
Group type: COMPARATOR
Intervention: Right Ventricular (RV) Pacing
Number of subjects: 91
Study 27908615 — intervention group
Group type: EXPERIMENTAL
Intervention: PLIF using double expandable PEEK cages without instrumentation (Group 2)
Number of subjects: 60
Study 27908615 — intervention group
Group type: COMPARATOR
Intervention: Simple discectomy (Group 1)
Number of subjects: 60
Study 25682401 — intervention group
Group type: EXPERIMENTAL
Intervention: Joshi's external stabilization system (JESS fixator)
Number of subjects: 50
Study 25682401 — intervention group
Group type: COMPARATOR
Intervention: Complete subtalar release (Simons technique)
Number of subjects: 50
Study 23508277 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 g iodine/kg of TBW (n=33)
Number of subjects: 103
Study 23508277 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 g iodine/kg of LBW (n=35)
Number of subjects: 103
Study 23508277 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 g iodine/m(2) BSA (n=35)
Number of subjects: 103
Study 21414998 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-tailoring print-based intervention
Number of subjects: 325
Study 21414998 — intervention group
Group type: COMPARATOR
Intervention: Generic intervention
Number of subjects: 325
Study 19324419 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 788
Study 19324419 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine/Fluoxetine Combination (OFC; 6/25, 6/50, or 12/50 mg/day)
Number of subjects: 788
Study 19324419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 788
Study 17024635 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive endurance training (3 to 6 x 90 minute sessions per week at 70% V.O2max)
Number of subjects: 20
Study 17024635 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive endurance training
Number of subjects: 20
Study 17024635 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 20
Study 14967363 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month triptorelin SR
Number of subjects: 72
Study 14967363 — intervention group
Group type: COMPARATOR
Intervention: 28-day triptorelin SR
Number of subjects: 72
Study 11915622 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental fluoride-releasing tooth separator (polyurethane elastomer with tin fluoride)
Number of subjects: 0
Study 11915622 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9564446 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately suprathreshold dose
Number of subjects: 11
Study 9564446 — intervention group
Group type: COMPARATOR
Intervention: High dose
Number of subjects: 11
Study 7769501 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g purified fish oil once a day for 6 months
Number of subjects: 350
Study 7769501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 30078106 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training (1-min sprints with 2 min active recovery, 3 days/week for 6 weeks)
Number of subjects: 12
Study 30078106 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training
Number of subjects: 12
Study 30078106 — intervention group
Group type: COMPARATOR
Intervention: High-intensity training and Control
Number of subjects: 12
Study 27652697 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 66
Study 27652697 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 66
Study 27652697 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% mepivacaine with 1:100,000 epinephrine
Number of subjects: 66
Study 24345834 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (200 mg/day)
Number of subjects: 48
Study 24345834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 22310398 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral compartment starting point
Number of subjects: 60
Study 22310398 — intervention group
Group type: COMPARATOR
Intervention: Central compartment starting point
Number of subjects: 60
Study 19486477 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training (8 weeks)
Number of subjects: 21
Study 19486477 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 18679788 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-class words
Number of subjects: 12
Study 18679788 — intervention group
Group type: COMPARATOR
Intervention: Closed-class words
Number of subjects: 12
Study 15723745 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish Oil (FO) - 30 mL/d providing 4.9 g of eicosapentaenoic acid and 3.2 g of docosahexanoic acid for 4 weeks
Number of subjects: 24
Study 15723745 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (MLT) - 18 mg/d for 4 weeks
Number of subjects: 24
Study 15723745 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Fish Oil and Melatonin for the next 4 weeks
Number of subjects: 24
Study 15723745 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 24
Study 12818444 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH-HP and hMG (Group A)
Number of subjects: 45
Study 12818444 — intervention group
Group type: COMPARATOR
Intervention: FSH-HP only (Group B)
Number of subjects: 45
Study 10397212 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) treatment (150 mg/kg bolus followed by continuous infusion of 12 mg/kg/hr)
Number of subjects: 86
Study 10397212 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 86
Study 8873520 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free hernioplasty with prolene mesh
Number of subjects: 208
Study 8873520 — intervention group
Group type: COMPARATOR
Intervention: Cooper ligament repair
Number of subjects: 208
Study 8873520 — intervention group
Group type: COMPARATOR
Intervention: Abdominal ring repair
Number of subjects: 208
Study 8873520 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free hernioplasty for primary direct inguinal hernias
Number of subjects: 208
Study 8873520 — intervention group
Group type: COMPARATOR
Intervention: Tension-free hernioplasty vs conventional herniotomies
Number of subjects: 208
Study 1984216 — intervention group
Group type: EXPERIMENTAL
Intervention: TM‐2420 ambulatory blood pressure monitor
Number of subjects: 30
Study 6336898 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 354
Study 6336898 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 354
Study 6336898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study 29614706 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga- and meditation-based lifestyle intervention (YMLI)
Number of subjects: 58
Study 29614706 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study 27515720 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice guideline for optimal symptom relief (intervention group)
Number of subjects: 367
Study 27515720 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 367
Study 24658476 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedian approach
Number of subjects: 74
Study 24658476 — intervention group
Group type: COMPARATOR
Intervention: Midline approach
Number of subjects: 74
Study 22414611 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic coordinated reset (CR) neuromodulation
Number of subjects: 63
Study 22414611 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 63
Study 20460477 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel plus ASA404 1,200 mg/m2 (A-D)
Number of subjects: 74
Study 20460477 — intervention group
Group type: COMPARATOR
Intervention: docetaxel 75 mg/m2 alone (D)
Number of subjects: 74
Study 19013751 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine infiltration (40 ml of ropivacaine 4.75 mg/ml)
Number of subjects: 81
Study 19013751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 15823991 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface electrical stimulation (ES) for 20 min once daily, 6 days per week for 1 month
Number of subjects: 24
Study 15823991 — intervention group
Group type: COMPARATOR
Intervention: Control group (ES with stimulation intensity kept at zero)
Number of subjects: 24
Study 12779107 — intervention group
Group type: EXPERIMENTAL
Intervention: DentiPatch (20% lidocaine)
Number of subjects: 28
Study 12779107 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthetic (Hurricaine Dry Handle Swab, 20% benzocaine)
Number of subjects: 28
Study 10348415 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapy
Number of subjects: 0
Study 10348415 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 7791286 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTon (PT)
Number of subjects: 85
Study 7791286 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometer (GAT)
Number of subjects: 85
Study 7791286 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PT and GAT
Number of subjects: 85
Study 7791286 — intervention group
Group type: COMPARATOR
Intervention: Comparison of central and peripheral IOP
Number of subjects: 85
Study 1782305 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine
Number of subjects: 12
Study 1782305 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine
Number of subjects: 12
Study 1782305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6801096 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 8
Study 6801096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30829753 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CO2 laser followed by topical 5‐fluorouracil (5‐FU) application
Number of subjects: 30
Study 30829753 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CO2 laser followed by topical verapamil hydrochloride application
Number of subjects: 30
Study 30829753 — intervention group
Group type: COMPARATOR
Intervention: CO2 laser monotherapy
Number of subjects: 30
Study 29059409 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended (4-week run-in)
Number of subjects: 58
Study 29059409 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended + FE
Number of subjects: 58
Study 29059409 — intervention group
Group type: COMPARATOR
Intervention: Standard (1-week run-in)
Number of subjects: 58
Study 27255954 — intervention group
Group type: EXPERIMENTAL
Intervention: No Endotracheal suction group ('No ET' Group)
Number of subjects: 175
Study 27255954 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal suction group ('ET' Group)
Number of subjects: 175
Study 24596911 — intervention group
Group type: EXPERIMENTAL
Intervention: Denture adhesive cream
Number of subjects: 30
Study 24596911 — intervention group
Group type: EXPERIMENTAL
Intervention: Denture adhesive strips
Number of subjects: 30
Study 24596911 — intervention group
Group type: COMPARATOR
Intervention: Nonadhesive trial
Number of subjects: 30
Study 23152962 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-only 0.7 g/kg/day in 2 divided doses
Number of subjects: 96
Study 23152962 — intervention group
Group type: COMPARATOR
Intervention: PEG-EL 6.9 g in 1-4 sachets according to age for 4 weeks
Number of subjects: 96
Study 20364686 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clinical homeopathy and dynamic electrical neurostimulation (DENS)
Number of subjects: 0
Study 20364686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18681276 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) at a concentration of 25 mg/mL applied topically for 1 minute, 4 times after tendon repair
Number of subjects: 48
Study 18681276 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 48
Study 15572656 — intervention group
Group type: EXPERIMENTAL
Intervention: Lengthening contractions (LC); average peak torque = 299 ± 18 N.m
Number of subjects: 8
Study 15572656 — intervention group
Group type: COMPARATOR
Intervention: Shortening contractions (SC); average peak torque = 225 ± 7 N.m
Number of subjects: 8
Study 12934466 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-cytokine therapy targeting TNF-alpha, IL-1, and IF-gamma
Number of subjects: 0
Study 12934466 — intervention group
Group type: EXPERIMENTAL
Intervention: New low-molecular inhibitors of cytokines
Number of subjects: 0
Study 12934466 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of anti-cytokines with other antirheumatic drugs
Number of subjects: 0
Study 11096191 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculin (PPD) test (0.1 ml of PPD, 2 TU)
Number of subjects: 20
Study 11096191 — intervention group
Group type: COMPARATOR
Intervention: Sodium lauryl sulphate
Number of subjects: 20
Study 9072780 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole
Number of subjects: 20
Study 9072780 — intervention group
Group type: COMPARATOR
Intervention: 20 mg omeprazole
Number of subjects: 20
Study 1443741 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 10 micrograms
Number of subjects: 24
Study 1443741 — intervention group
Group type: COMPARATOR
Intervention: Epidural sufentanil 10 micrograms
Number of subjects: 24
Study 1443741 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sufentanil 10 micrograms
Number of subjects: 24
Study 3510278 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMP (cyclophosphamide, doxorubicin, methotrexate, and procarbazine)
Number of subjects: 486
Study 3510278 — intervention group
Group type: EXPERIMENTAL
Intervention: MVP (mitomycin, vinblastine, and cisplatin)
Number of subjects: 486
Study 3510278 — intervention group
Group type: EXPERIMENTAL
Intervention: VP-P (etoposide and cisplatin)
Number of subjects: 486
Study 3510278 — intervention group
Group type: EXPERIMENTAL
Intervention: VDA-P (vindesine and cisplatin)
Number of subjects: 486
Study 3510278 — intervention group
Group type: COMPARATOR
Intervention: Overall
Number of subjects: 486
Study 30902023 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored advice based on mental health status
Number of subjects: 6323
Study 30902023 — intervention group
Group type: COMPARATOR
Intervention: General advice following assessment of mental health status
Number of subjects: 6323
Study 30902023 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (screening and control)
Number of subjects: 6323
Study 31913911 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 10 mg (given twice, 2 hours apart)
Number of subjects: 30
Study 31913911 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 10 mg and Ondansetron 4 mg (given simultaneously)
Number of subjects: 30
Study 31913911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31725826 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of oxaliplatin-based adjuvant chemotherapy
Number of subjects: 0
Study 31725826 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of oxaliplatin-based adjuvant chemotherapy
Number of subjects: 0
Study 30332403 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (PZQ) at a single dose of 40 mg/kg
Number of subjects: 400
Study 26179124 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (initiated at 10 mg every other day, titrated to a maximum of 40 mg/day over 16 weeks)
Number of subjects: 11
Study 26179124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 26179124 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 11
Study 22407196 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide (IB); nebulized, administered at 30-minute intervals for 2 hours
Number of subjects: 124
Study 22407196 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4); combined nebulized and intravenous bolus, administered at 30-minute intervals for 2 hours
Number of subjects: 124
Study 22950884 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent decision model for rating drug-drug interactions
Number of subjects: 200
Study 19803687 — intervention group
Group type: COMPARATOR
Intervention: THC 0.0 mg
Number of subjects: 16
Study 19803687 — intervention group
Group type: EXPERIMENTAL
Intervention: THC 29.3 mg
Number of subjects: 16
Study 19803687 — intervention group
Group type: EXPERIMENTAL
Intervention: THC 49.1 mg
Number of subjects: 16
Study 19803687 — intervention group
Group type: EXPERIMENTAL
Intervention: THC 69.4 mg
Number of subjects: 16
Study 17653309 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegasys, 180 ug injected subcutaneously once a week for 24 weeks
Number of subjects: 98
Study 17653309 — intervention group
Group type: EXPERIMENTAL
Intervention: Roferon-A 3 MU three times a week for 24 weeks
Number of subjects: 98
Study 16116879 — intervention group
Group type: EXPERIMENTAL
Intervention: CarboMedics Reduced (CM‐R) valve
Number of subjects: 20
Study 16116879 — intervention group
Group type: COMPARATOR
Intervention: Medtronic Hall (MH) valve
Number of subjects: 20
Study 12394655 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet + statin treatment
Number of subjects: 1926
Study 10853568 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2%
Number of subjects: 50
Study 10853568 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2% with epinephrine 1:80,000
Number of subjects: 50
Study 7848072 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine training position (SUP, n = 7)
Number of subjects: 14
Study 7848072 — intervention group
Group type: COMPARATOR
Intervention: Sitting training position (SIT, n = 7)
Number of subjects: 14
Study 7848072 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SUP and SIT groups
Number of subjects: 14
Study 2277567 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL 1% lidocaine solution injected through the catheter on the tube.
Number of subjects: 30
Study 2277567 — intervention group
Group type: COMPARATOR
Intervention: 2 mL 2% lidocaine solution injected through the catheter on the tube.
Number of subjects: 30
Study 6993112 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornidazole
Number of subjects: 226
Study 6993112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 31371228 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) followed by routine adjuvant systemic chemotherapy
Number of subjects: 204
Study 31371228 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant systemic chemotherapy alone
Number of subjects: 204
Study 31371228 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant HIPEC
Number of subjects: 204
Study 27583685 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine 0.25% antiseptic wipes
Number of subjects: 218
Study 27583685 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chlorhexidine)
Number of subjects: 218
Study 26504148 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg/day for 14 days)
Number of subjects: 156
Study 26504148 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 156
Study 24922355 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS and CT (group A)
Number of subjects: 72
Study 24922355 — intervention group
Group type: COMPARATOR
Intervention: EUS only (group B)
Number of subjects: 72
Study 22459542 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Number of subjects: 459
Study 22459542 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg
Number of subjects: 459
Study 22459542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study 21123503 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented kinematic feedback (F, M, FM)
Number of subjects: 32
Study 21123503 — intervention group
Group type: COMPARATOR
Intervention: KR‐only (control)
Number of subjects: 32